An investigational drug that targets an instigator of the TDP-43 protein, a well-known hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), may reduce the protein's buildup and neurological decline associated with these disorders, suggests a pre-clinical study.
from Health & Medicine News -- ScienceDaily https://www.sciencedaily.com/releases/2020/09/200908131036.htm
No comments:
Post a Comment